| BEMAX | VEMIX | BEMAX / VEMIX | |
| Total Expense Ratio | 1.32 | 0.09 | 1,467% |
| Annual Report Gross Expense Ratio | 1.32 | 0.09 | 1,467% |
| Fund Existence | 15 years | 26 years | - |
| Gain YTD | 46.508 | 21.721 | 214% |
| Front Load | 6% | N/A | - |
| Min. Initial Investment | 2500 | 5000000 | 0% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 973M | 141B | 1% |
| Annual Yield % from dividends | 2.24 | 2.82 | 80% |
| Returns for 1 year | 44.67 | 20.22 | 221% |
| Returns for 3 years | 85.19 | 46.12 | 185% |
| Returns for 5 years | 61.40 | 20.62 | 298% |
| Returns for 10 years | 125.39 | 89.03 | 141% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IHE | 86.21 | 0.86 | +1.01% |
| iShares US Pharmaceuticals ETF | |||
| IWFL | 59.15 | 0.29 | +0.48% |
| ETRACS 2x Leveraged US Gr Fctr TR ETN | |||
| SCHF | 24.14 | 0.05 | +0.21% |
| Schwab International Equity ETF™ | |||
| FDTX | 41.24 | 0.08 | +0.19% |
| Fidelity Disruptive Technology ETF | |||
| XCNY | 27.98 | -0.05 | -0.19% |
| SPDR S&P Emerging Markets ex-China ETF | |||